-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Thermo Fisher Scientific's Income Statement
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$39.21 B | $44.92 B | $42.86 B | $42.88 B | $44.56 B |
| Cost of Revenue |
|
$19.58 B | $25.90 B | $25.66 B | $25.15 B | $27.78 B |
| Gross Profit |
|
$19.63 B | $19.01 B | $17.19 B | $17.73 B | $16.78 B |
| Research & Development |
|
$1.41 B | $1.47 B | $1.34 B | $1.39 B | $1.40 B |
| Selling,General & Administrative |
|
$7.91 B | $9.02 B | $8.41 B | $8.68 B | $7.27 B |
| Operating Expense |
|
$9.32 B | $10.49 B | $9.75 B | $10.07 B | $8.67 B |
| Operating Income |
|
$10.32 B | $8.53 B | $7.45 B | $7.66 B | $8.11 B |
| Net Income |
|
$7.73 B | $6.95 B | $6.00 B | $6.34 B | $6.74 B |
Thermo Fisher Scientific's Balance Sheet
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$4.48 B | $8.52 B | $8.08 B | $5.57 B | $10.11 B |
| Inventories |
|
$5.05 B | $5.63 B | $5.09 B | $4.98 B | $5.43 B |
| Total Current Assets |
|
$20.11 B | $25.23 B | $24.59 B | $22.14 B | $28.71 B |
| Property,Plant and Equipment |
|
$9.86 B | $10.87 B | $11.00 B | $10.80 B | $10.57 B |
| Goodwill |
|
$41.92 B | $41.20 B | $44.02 B | $45.85 B | $49.36 B |
| Total Assets |
|
$95.12 B | $97.15 B | $98.73 B | $97.32 B | $110.34 B |
| Total Liabilities |
|
$54.15 B | $53.01 B | $51.88 B | $47.65 B | $56.81 B |
| Retained Earnings |
|
$35.43 B | $41.91 B | $47.36 B | $53.10 B | - |
| Total Shareholder Equity |
|
$40.79 B | $43.98 B | $46.74 B | $49.58 B | $53.42 B |
| Common Stock |
|
$439.00 M | $441.00 M | $442.00 M | $444.00 M | - |
Thermo Fisher Scientific's Cash flow
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$2.59 B | $3.38 B | $3.41 B | $3.11 B | $2.78 B |
| Dividends Payout |
|
-$395.00 M | -$455.00 M | -$523.00 M | -$583.00 M | -$636.00 M |
| Capital Expenditures (Capex) |
|
-$2.52 B | -$2.24 B | -$1.48 B | -$1.40 B | -$1.53 B |
| Free Cash Flow (FCF) |
|
$7.02 B | $6.91 B | $6.93 B | $7.27 B | $6.29 B |
Thermo Fisher Scientific's Profitability
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$19.63 B | $19.01 B | $17.19 B | $17.73 B | $16.78 B |
| Gross Profit Margin (%) |
|
50.07% | 42.33% | 40.12% | 41.34% | 37.66% |
| Operating Income |
|
$10.32 B | $8.53 B | $7.45 B | $7.66 B | $8.11 B |
| Operating Income Margin (%) |
|
26.31% | 18.98% | 17.37% | 17.87% | 18.20% |
| Net Income |
|
$7.73 B | $6.95 B | $6.00 B | $6.34 B | $6.74 B |
| Net Income Margin (%) |
|
19.70% | 15.47% | 13.99% | 14.77% | 15.12% |
| EBITDA |
|
$11.97 B | $11.94 B | $11.20 B | $11.80 B | $10.89 B |
| EBITDA Margin (%) |
|
30.52% | 26.59% | 26.12% | 27.52% | 24.44% |
Thermo Fisher Scientific's Ratios
| Chart | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
18.94% | 15.80% | 12.83% | 12.78% | - |
| Return on Assets (ROA) |
|
8.12% | 7.15% | 6.07% | 6.51% | - |
| Debt to Equity |
|
89.08% | 82.03% | 77.94% | 66.10% | 73.73% |
| Debt to total asset |
|
38.20% | 37.13% | 36.89% | 33.68% | 35.69% |
| Enterprise value to revenue |
|
7.52 | 5.42 | 5.44 | 5.31 | 0.00 |
| Enterprise value to EBITDA |
|
24.63 | 20.38 | 20.83 | 19.28 | 0.00 |
| Enterprise value |
|
$294.75 B | $243.42 B | $233.23 B | $227.49 B | - |
| Tax Rate (%) |
|
12.55% | 9.17% | 4.55% | 9.39% | 7.53% |
Frequently Asked Questions
